Table 2.

RR of treatment with ACEI/ARB versus no treatmenta

Patient SubpopulationNo. of PatientsGraft SurvivalPatient Survival
RRP95% CIRRP95% CI
Diabetic nephropathy11530.820.300.56 to 1.200.680.090.43 to 1.06
Hypertensive nephropathy11281.120.590.75 to 1.671.400.200.84 to 2.35
Pretransplantation cardiovascular risk10300.950.810.65 to 1.401.050.810.69 to 1.61
Recipient age <60 yr14,6031.040.540.92 to 1.170.960.680.80 to 1.16
Recipient age ≥60 yr24291.050.710.82 to 1.341.150.340.86 to 1.54
1-yr systolic BP <140 mmHg98080.980.800.82 to 1.160.860.240.67 to 1.10
1-yr systolic BP ≥140 mmHg68691.080.310.93 to 1.251.130.250.92 to 1.41
1-yr serum cholesterol <200 mg/dl61970.970.750.78 to 1.200.920.580.68 to 1.24
1-yr serum cholesterol ≥200 mg/dl75931.020.810.87 to 1.191.040.740.83 to 1.30
1-yr serum creatinine <130 μmol/L95741.060.550.87 to 1.290.990.950.77 to 1.27
1-yr serum creatinine ≥130 μmol/L74611.030.620.91 to 1.181.030.790.84 to 1.26
  • a Recipients of first kidney transplants from deceased donors were analyzed from 2 to 6 yr of follow-up. ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers.